Confo Therapeutics appoints Dr Cedric Ververken as Chief Executive Officer
Brussels, Belgium: 7 September 2016 - Confo Therapeutics, an emerging drug discovery company, announces the appointment of Cedric Ververken as CEO and board member, starting October 1. Dr Ververken will lead the transition of Confo Therapeutics from a technology company to a drug development company.
Cedric Ververken joins Confo Therapeutics from Ablynx, where he advanced through positions of increasing responsibility, most recently as Vice President Business Development heading the company's partnering activities around specific products and Nanobody drug discovery collaborations with top tier pharmaceutical companies. He started his career as scientist-project manager heading cross functional R&D teams and advancing internal and partnered R&D programs. Dr Ververken has a PhD in bioscience engineering from KU Leuven.
More info on Confo Therapeutics' website.
Next > FDA clears icometrix’ image quantification software to monitor neurological disorders such as Multiple Sclerosis
Previous > FRX Polymers Inc secures US$ 22 million in Series D equity financing